This website does readability filtering of other pages. All styles, scripts, forms and ads are stripped. If you want your website excluded or have other feedback, use this form.

FDA Approves Takhzyro (lanadelumab-flyo) for Hereditary Angioedema

Skip to Content

Register Sign In Menu
Print Share

FDA Approves Takhzyro

FDA Approves Takhzyro (lanadelumab-flyo) for Hereditary Angioedema

Print this page

August 23, 2018 -- The U.S. Food and Drug Administration today approved Takhzyro (lanadelumab), the first monoclonal antibody approved in the U.S. to treat patients 12 years and older with types I and II hereditary angioedema (HAE). HAE is a rare and serious genetic disease that affects people with low levels of and poorly functioning C1-INH proteins in the body. This results in recurrent, unpredictable episodes of severe swelling in different areas of the body, including the stomach, limbs, face and throat.

Takhzyro is a plasma kallikrein inhibitor that is used to prevent swelling attacks from occurring. Takhzyro is a fully human IgG1 monoclonal antibody made in recombinant Chinese Hamster Ovary cells. This approval gives patients and healthcare professionals an additional treatment option.

HAE affects an estimated 1 in 50,000 men and women. Type I is the most common, and accounts for 85 percent of cases. Symptoms of HAE typically begin in childhood and worsen following puberty. Some patients may have many attacks each month, while others will go months without an attack.

FDA based its approval on data from a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in 125 patients with HAE. Patients who received Takhzyro had clinically meaningful and statistically significant reductions in the rate of investigator-confirmed HAE attacks compared to placebo over a 6-month treatment period.

The most common adverse drug reactions in patients taking Takhzyro in clinical trials are injection site reactions, upper respiratory infections, headache, rash, muscle pain, dizziness and diarrhea.

The FDA granted this application Priority Review and Breakthrough Therapy designation. Takhzyro also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases.

Source: FDA

Posted: August 2018

Related Articles:

Takhzyro (lanadelumab-flyo) FDA Approval History

More News Resources

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Drug Status

Rx Availability Prescription only Pregnancy & Lactation Risk data available N/A CSA Schedule* Not a controlled drug Approval History Drug history at FDA Recently Approved
  • Reyvow

    Reyvow (lasmiditan) is a serotonin (5-HT) 1F receptor agonist indicated for the...

  • Scenesse

    Scenesse (afamelanotide) is a selective agonist of the melanocortin 1 receptor...

  • Beovu

    Beovu (brolucizumab-dbll) is a human vascular endothelial growth factor (VEGF)...

  • Bonsity

    Bonsity (teriparatide) is a parathyroid hormone analog (PTH 1-34) indicated for...

More

Subscribe to our newsletters Subscribe to RSS Feeds

Drugs.com Mobile Apps

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Explore Apps

Support

About

Terms & Privacy

Subscribe to Drugs.com newsletters for the latest medication news, alerts, new drug approvals and more.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include IBM Watson Micromedex (updated 1 Oct 2019), Cerner Multum™ (updated 1 Oct 2019), Wolters Kluwer™ (updated 30 Sep 2019) and others.

Hide